10-Q quarterly report · filed Nov 4, 2026

UNITED THERAPEUTICS Corp (UTHR) Q3 2026 10-Q Quarterly Report

Short answer

UNITED THERAPEUTICS Corp (UTHR) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $833M (up 4.1% year over year) with net income of $259M.

Q3 2026 key financials · XBRL

Revenue
$833M
+4.1% YoY · +6.3% QoQ
Net income
$259M
−23.6% YoY · −22.3% QoQ
Operating margin
37.0%
Gross margin
88.1%
EPS (diluted)
$5.73
−19.9% YoY · −21.0% QoQ

Source: XBRL data from the UNITED THERAPEUTICS Corp (UTHR) Q3 2026 10-Q on SEC EDGAR. USD.

UNITED THERAPEUTICS Corp Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $832.5M, up from $799.5M YoY, a $33.0M increase
  • Total Tyvaso $503.8M, up 5% YoY; Tyvaso DPI $378.5M best performer, Nebulized Tyvaso $125.3M, down 12%
  • R&D expense $279.2M vs $127.5M YoY, driven by Thymmune acquisition and organ projects
  • Cash and investments $3,535.7M at September 30, down $1,161.3M from December 31; operating cash flow $1,083.4M
  • $3.0B share-repurchase authorization fully utilized; near-term growth expected from Tyvaso DPI, PH-ILD, ralinepag and IPF approval opportunities, with competition and pricing pressure headwinds

Risk Factors

  • New regulatory risk: FDA’s September 2026 OAI classification for sole-source ScinoPharm could delay ralinepag approval beyond June 24, 2027
  • Most material operational update: Yutrepia competition reduced Nebulized Tyvaso sales, with nine-month revenue down $81.5 million
  • Legal risk: 340B contract-pharmacy policy remains subject to potential HRSA or state enforcement despite favorable appellate rulings
  • Near-term reimbursement risk: Medicare Part D discounts increased to 10% initial-phase and 20% catastrophic-phase reductions
  • Financial risk: Cash and investments declined 25% to $3,535.7 million after $3.0 billion share repurchases热在线精品

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.